Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 925

1.

IVIg for relapsing-remitting multiple sclerosis: promises and uncertainties.

Bayry J, Hartung HP, Kaveri SV.

Trends Pharmacol Sci. 2015 May 20. pii: S0165-6147(15)00088-7. doi: 10.1016/j.tips.2015.04.012. [Epub ahead of print]

PMID:
26003802
2.

Long-term Therapy With Interleukin 6 Receptor Blockade in Highly Active Neuromyelitis Optica Spectrum Disorder.

Ringelstein M, Ayzenberg I, Harmel J, Lauenstein AS, Lensch E, Stögbauer F, Hellwig K, Ellrichmann G, Stettner M, Chan A, Hartung HP, Kieseier B, Gold R, Aktas O, Kleiter I.

JAMA Neurol. 2015 May 18. doi: 10.1001/jamaneurol.2015.0533. [Epub ahead of print]

PMID:
25985228
3.

Fingolimod induces the transition to a nerve regeneration promoting Schwann cell phenotype.

Heinen A, Beyer F, Tzekova N, Hartung HP, Küry P.

Exp Neurol. 2015 May 7;271:25-35. doi: 10.1016/j.expneurol.2015.05.002. [Epub ahead of print]

PMID:
25957629
4.

Dehydrated hereditary stomatocytosis masquerading as MDS.

Paessler M, Hartung H.

Blood. 2015 Mar 12;125(11):1841. No abstract available.

PMID:
25927085
5.

Pancytopenia in a patient with methylmalonic acidemia.

MacFarland S, Hartung H.

Blood. 2015 Mar 12;125(11):1840. No abstract available.

PMID:
25927084
6.

Efficacy and safety of Alemtuzumab in treatment-naive patients with relapsing-remitting multiple sclerosis: Four-year follow-up of the Care-MS I study.

Montalban X, Inshasi JS, Coles AJ, Hartung HP, Havrdova E, Selmaj KW, Margolin DH, Palmer J, Oyuela P.

Mult Scler Relat Disord. 2014 Nov;3(6):761-2. doi: 10.1016/j.msard.2014.09.207. Epub 2014 Nov 21.

PMID:
25891612
7.

Efficacy and safety of alemtuzumab in patients with relapsing-remitting multiple sclerosis who relapsed on prior therapy: Four-year follow-up of the Care-MS II study.

Kieseier BC, Sahraian MA, Coles AJ, Hartung HP, Havrdova E, Selmaj KW, Margolin DH, Palmer J, Oyuela P.

Mult Scler Relat Disord. 2014 Nov;3(6):756. doi: 10.1016/j.msard.2014.09.194. Epub 2014 Nov 21.

PMID:
25891599
8.

Phase 2 BOLD extension study efficacy results for siponimod (BAF312) in patients with relapsing-remitting multiple sclerosis.

Stuve O, Hartung HP, Freedman M, Li D, Hemmer B, Kappos L, Rieckmann P, Montalban X, Ziemssen T, Selmaj K.

Mult Scler Relat Disord. 2014 Nov;3(6):754-5. doi: 10.1016/j.msard.2014.09.190. Epub 2014 Nov 21.

PMID:
25891595
9.

Effect of prior treatment status and reasons for discontinuation on the efficacy and safety of fingolimod vs. interferon β-1a intramuscular: Subgroup analyses of the Trial Assessing Injectable Interferon vs. Fingolimod Oral in Relapsing-Remitting Multiple Sclerosis (TRANSFORMS).

Khatri BO, Pelletier J, Kappos L, Hartung HP, Comi G, Barkhof F, von Rosenstiel P, Meng X, Grinspan A, Hashmonay R, Cohen JA; TRANSFORMS Study Group.

Mult Scler Relat Disord. 2014 May;3(3):355-63. doi: 10.1016/j.msard.2013.11.006. Epub 2013 Dec 12.

PMID:
25876473
10.

Electrical stimulation alleviates depressive-like behaviors of rats: investigation of brain targets and potential mechanisms.

Lim LW, Prickaerts J, Huguet G, Kadar E, Hartung H, Sharp T, Temel Y.

Transl Psychiatry. 2015 Mar 31;5:e535. doi: 10.1038/tp.2015.24.

11.

Emergence of clonal hematopoiesis in the majority of patients with acquired aplastic anemia.

Babushok DV, Perdigones N, Perin JC, Olson TS, Ye W, Roth JJ, Lind C, Cattier C, Li Y, Hartung H, Paessler ME, Frank DM, Xie HM, Cross S, Cockroft JD, Podsakoff GM, Monos D, Biegel JA, Mason PJ, Bessler M.

Cancer Genet. 2015 Apr;208(4):115-28. doi: 10.1016/j.cancergen.2015.01.007. Epub 2015 Feb 2.

PMID:
25800665
12.

Dimethyl fumarate in relapsing-remitting multiple sclerosis: rationale, mechanisms of action, pharmacokinetics, efficacy and safety.

Dubey D, Kieseier BC, Hartung HP, Hemmer B, Warnke C, Menge T, Miller-Little WA, Stuve O.

Expert Rev Neurother. 2015 Apr;15(4):339-46. doi: 10.1586/14737175.2015.1025755.

PMID:
25800129
13.

Gaps between aims and achievements in therapeutic modification of neuronal damage ("neuroprotection").

Wiendl H, Elger C, Förstl H, Hartung HP, Oertel W, Reichmann H, Schwab S.

Neurotherapeutics. 2015 Apr;12(2):449-54. doi: 10.1007/s13311-015-0348-8.

14.

Follow-up nerve conduction studies in CIDP after treatment with IGIV-C: Comparison of patients with and without subsequent relapse.

Chin RL, Deng C, Bril V, Hartung HP, Merkies IS, Donofrio PD, van Doorn PA, Dalakas MC, Latov N.

Muscle Nerve. 2015 Feb 27. doi: 10.1002/mus.24624. [Epub ahead of print]

PMID:
25728021
15.

Conversion from clinically isolated syndrome to multiple sclerosis: A large multicentre study.

Kuhle J, Disanto G, Dobson R, Adiutori R, Bianchi L, Topping J, Bestwick J, Meier UC, Marta M, Costa GD, Runia T, Evdoshenko E, Lazareva N, Thouvenot E, Iaffaldano P, Direnzo V, Khademi M, Piehl F, Comabella M, Sombekke M, Killestein J, Hegen H, Rauch S, D'Alfonso S, Alvarez-Cermeño J, Kleinová P, Horáková D, Roesler R, Lauda F, Llufriu S, Avsar T, Uygunoglu U, Altintas A, Saip S, Menge T, Rajda C, Bergamaschi R, Moll N, Khalil M, Marignier R, Dujmovic I, Larsson H, Malmestrom C, Scarpini E, Fenoglio C, Wergeland S, Laroni A, Annibali V, Romano S, Martínez A, Carra A, Salvetti M, Uccelli A, Torkildsen Ø, Myhr K, Galimberti D, Rejdak K, Lycke J, Frederiksen J, Drulovic J, Confavreux C, Brassat D, Enzinger C, Fuchs S, Bosca I, Pelletier J, Picard C, Colombo E, Franciotta D, Derfuss T, Lindberg R, Yaldizli Ö, Vécsei L, Kieseier B, Hartung H, Villoslada P, Siva A, Saiz A, Tumani H, Havrdová E, Villar L, Leone M, Barizzone N, Deisenhammer F, Teunissen C, Montalban X, Tintoré M, Olsson T, Trojano M, Lehmann S, Castelnovo G, Lapin S, Hintzen R, Kappos L, Furlan R, Martinelli V, Comi G, Ramagopalan S, Giovannoni G.

Mult Scler. 2015 Feb 13. pii: 1352458514568827. [Epub ahead of print]

PMID:
25680984
16.

Redox-regulated fate of neural stem progenitor cells.

Prozorovski T, Schneider R, Berndt C, Hartung HP, Aktas O.

Biochim Biophys Acta. 2015 Aug;1850(8):1543-1554. doi: 10.1016/j.bbagen.2015.01.022. Epub 2015 Feb 7. Review.

PMID:
25662818
17.

Natalizumab restores aberrant miRNA expression profile in multiple sclerosis and reveals a critical role for miR-20b.

Ingwersen J, Menge T, Wingerath B, Kaya D, Graf J, Prozorovski T, Keller A, Backes C, Beier M, Scheffler M, Dehmel T, Kieseier BC, Hartung HP, Küry P, Aktas O.

Ann Clin Transl Neurol. 2015 Jan;2(1):43-55. doi: 10.1002/acn3.152. Epub 2014 Dec 5.

18.

Axonal damage in papilledema linked to idiopathic intracranial hypertension as revealed by multifocal visual evoked potentials.

Hartmann CJ, Klistorner AI, Brandt AU, Schroeder K, Kolbe R, Cohn E, Goebels N, Guthoff R, Aktas O, Hartung HP, Albrecht P.

Clin Neurophysiol. 2014 Dec 27. pii: S1388-2457(14)00858-X. doi: 10.1016/j.clinph.2014.12.014. [Epub ahead of print] No abstract available.

PMID:
25613033
19.

Oligodendroglial maturation is dependent on intracellular protein shuttling.

Göttle P, Sabo JK, Heinen A, Venables G, Torres K, Tzekova N, Parras CM, Kremer D, Hartung HP, Cate HS, Küry P.

J Neurosci. 2015 Jan 21;35(3):906-19. doi: 10.1523/JNEUROSCI.1423-14.2015.

20.

Subtle retinal pathology in amyotrophic lateral sclerosis.

Ringelstein M, Albrecht P, Südmeyer M, Harmel J, Müller AK, Keser N, Finis D, Ferrea S, Guthoff R, Schnitzler A, Hartung HP, Methner A, Aktas O.

Ann Clin Transl Neurol. 2014 Apr;1(4):290-7. doi: 10.1002/acn3.46. Epub 2014 Mar 11.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk